The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer
Egile, Coumaran, Kenigsberg, Mireille, Delaisi, Christine, Bégassat, Françoise, Do-Vale, Véronique, Mestadier, Jessica, Bonche, Fabrice, Bénard, Tsiala, Nicolas, Jean-Paul, Valence, Sandrine, Lefranc, Céline, Francesconi, Elisa, Castell, Christelle, Lefebvre, Anne-Marie, Nemecek, Conception, Calvet, Loreley, Goulaouic, Hélène
Published in Molecular cancer therapeutics (01.02.2015)
Published in Molecular cancer therapeutics (01.02.2015)
Get full text
Journal Article
Abstract 845: In vitro and in vivo pharmacology of SAR125844, a potent and selective intravenous MET kinase inhibitor undergoing Phase I clinical trial
Goulaouic, Hélène, Kenigsberg, Mireille, Delaisi, Christine, Begassat, Françoise, Do-Vale, Véronique, Mestadier, Jessica, Bonche, Fabrice, Bénard, Tsiala, Nicolas, Jean-Paul, Calvet, Loreley, Egile, Coumaran, Nemecek, Conception, Lengauer, Christoph
Published in Cancer research (Chicago, Ill.) (15.04.2012)
Published in Cancer research (Chicago, Ill.) (15.04.2012)
Get full text
Journal Article